| 赵晓昕,董 严,顾 焱,陈艳荣,欧娟娟.RCN2和PEAK1在结直肠癌中的表达与临床病理特征及预后的关系[J].现代生物医学进展英文版,2019,19(12):2299-2303. |
| RCN2和PEAK1在结直肠癌中的表达与临床病理特征及预后的关系 |
| The Expressions of RCN2 and PEAK1 in the Colorectal Cancer and the Correlations with the Clinicopathological Characteristics and the Prognosis |
| Received:October 27, 2018 Revised:November 22, 2018 |
| DOI：10.13241/j.cnki.pmb.2019.12.021 |
| 中文关键词: RCN2 PEAK1 结直肠癌 临床病理特征 预后 相关性 |
| 英文关键词: RCN2 PEAK1 Colorectal cancer Clinicopathological characteristics Prognosis Correlation |
| 基金项目:重庆市社会民生科技创新专项（cstc2015shmszx120058） |
| Author Name | Affiliation | E-mail | | ZHAO Xiao-xin | Department of Oncology, First Affiliated Hospital of Army Medical University, Chongqing, 400038, China | 13808393971@139.com | | DONG Yan | Department of Oncology, First Affiliated Hospital of Army Medical University, Chongqing, 400038, China | | | GU Yan | Department of Oncology, First Affiliated Hospital of Army Medical University, Chongqing, 400038, China | | | CHEN Yan-rong | Department of Oncology, First Affiliated Hospital of Army Medical University, Chongqing, 400038, China | | | OU Juan-juan | Department of Oncology, First Affiliated Hospital of Army Medical University, Chongqing, 400038, China | |
|
| Hits: 1022 |
| Download times: 786 |
| 中文摘要: |
| 摘要 目的：检测网织钙结合蛋白2（RCN2）和伪足富集的非典型激酶1（PEAK1）蛋白在结直肠癌组织中的表达情况，分析RCN2和PEAK1表达与患者临床病理特征和预后的关系。方法：免疫组织化学法检测90例结直肠癌组织及其癌旁正常组织中RCN2和PEAK1蛋白表达情况，分析结直肠癌组织RCN2和PEAK1表达与患者临床病理特征的关系，Kaplan-Meier生存曲线分析RCN2和PEAK1表达对患者预后的影响，Spearman等级相关检验结直肠癌组织RCN2和PEAK1表达的相关性。结果：RCN2和PEAK1蛋白在结直肠癌组织中的阳性表达率均明显高于癌旁正常组织（P<0.05）。结直肠癌组织RCN2表达与肿瘤直径、浸润深度和TNM分期均有关（P<0.05），PEAK1表达与肿瘤浸润深度、淋巴结转移和TNM分期均有关（P<0.05）。Log Rank检验结果显示，RCN2阳性表达组和PEAK1阳性表达组患者的术后5年总生存率均分别低于RCN2阴性表达组和PEAK1阴性表达组患者（P<0.05）。结直肠癌组织RCN2和PEAK1表达呈正相关性（r=0.586，P=0.000）。结论：RCN2和PEAK1蛋白在结直肠癌组织中呈高表达，且均与肿瘤恶性进展和不良预后关系密切。RCN2和PEAK1可作为结直肠癌治疗靶标的候选分子。 |
| 英文摘要: |
| ABSTRACT Objective: To detect the protein expressions of reticulocalbin-2 (RCN2) and pseudopodium-enriched atypical kinase 1 (PEAK1) in the colorectal cancer tissues, to evaluate their correlations with the clinicopathological characteristics and prognosis. Methods: The immunohistochemistry assay was applied to detect the protein expressions of RCN2 and PEAK1 in 90 cases of the colorectal cancer tissues and the adjacent normal colorectal tissues. The correlations of RCN2/PEAK1 expression with the clinicopathological characteristics were analyzed, and the Kaplan-Meier survival curve was utilized to analyze the influence of RCN2/PEAK1 expression on the prognosis. Moreover, the Spearman was used to examine the correlation between the RCN2 and PEAK1 expression. Results: The positive rates of RCN2 and PEAK1 protein in the colorectal cancer tissues were higher than those in the adjacent normal colorectal tissues(P<0.05). In the colorectal cancer tissues, the RCN2 expression was positively correlated with the tumor size, the depth of invasion and the TNM stages(P<0.05), besides, the PEAK1 expression was positively correlated with the depth of invasion, the lymph node metastasis and the TNM stages(P<0.05). The Log Rank results showed that the 5-year overall survival rates in the RCN2-positive group and the PEAK1-positive group were both lower than those in the RCN2-negative group and the PEAK1-negative group, respectively(P<0.05). In the colorectal cancer tissues, there was a positive correlation between the RCN2 and PEAK1 expression(r=0.586, P=0.000). Conclusion: The RCN2 and PEAK1 protein are up-regulated in the colorectal cancer tissues, which was correlated with progression and poor prognosis. RCN2 and PEAK may be the candidates for the therapeutic biomarkers of colorectal cancer. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
